Free Trial
→ Executive Order 14241 Unleashes Trump’s New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annexon, Inc. stock logo
ANNX
Annexon
$3.92
-3.3%		$4.20
$2.54
▼
$7.18
$740.31M1.433.02 million shs1.00 million shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$2.09
+246.3%		$1.14
$0.56
▼
$2.72
$202.15M1.713.92 million shs176.59 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$223.92
+1.0%		$182.49
$22.28
▼
$254.48
$89.60B1.1612.63 million shs5.54 million shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$2.40
-6.8%		$3.04
$2.22
▼
$5.49
$716.97M2.33.18 million shs1.46 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annexon, Inc. stock logo
ANNX
Annexon
0.00%+8.00%-3.34%-22.86%+28.16%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%-32.85%-48.07%-13.55%-74.37%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+10.80%+16.69%+302.10%+716.35%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
0.00%+10.30%-11.07%-19.18%-48.08%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annexon, Inc. stock logo
ANNX
Annexon
$3.92
-3.3%		$4.20
$2.54
▼
$7.18
$740.31M1.433.02 million shs1.00 million shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$2.09
+246.3%		$1.14
$0.56
▼
$2.72
$202.15M1.713.92 million shs176.59 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$223.92
+1.0%		$182.49
$22.28
▼
$254.48
$89.60B1.1612.63 million shs5.54 million shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$2.40
-6.8%		$3.04
$2.22
▼
$5.49
$716.97M2.33.18 million shs1.46 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annexon, Inc. stock logo
ANNX
Annexon
0.00%+8.00%-3.34%-22.86%+28.16%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%-32.85%-48.07%-13.55%-74.37%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+10.80%+16.69%+302.10%+716.35%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
0.00%+10.30%-11.07%-19.18%-48.08%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Annexon, Inc. stock logo
ANNX
Annexon
2.40
Hold$15.29285.52% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.63
Moderate Buy$4.0095.79% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$107.10-52.36% Downside
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
2.75
Moderate Buy$9.60294.25% Upside

Current Analyst Ratings Breakdown

Latest INO, MRNA, ANNX, and SANA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/2/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price TargetNeutral ➝ Buy$5.00
11/2/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeNeutral ➝ Buy
10/27/2026
Moderna, Inc. stock logo
MRNA
Moderna
William Blair logo
William Blair
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeOutperform ➝ Market Perform
10/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$167.00 ➝ $230.00
10/23/2026
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell
10/21/2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/21/2026
Moderna, Inc. stock logo
MRNA
Moderna
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/21/2026
Moderna, Inc. stock logo
MRNA
Moderna
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetHold$40.00 ➝ $90.00
10/15/2026
Annexon, Inc. stock logo
ANNX
Annexon
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/15/2026
Moderna, Inc. stock logo
MRNA
Moderna
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$120.00 ➝ $137.00
10/12/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
(Data available from 11/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$1.42 per shareN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$60K3,520.77N/AN/A$0.36 per share5.68
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B46.17N/AN/A$22.14 per share10.15
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/A$0.60 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Annexon, Inc. stock logo
ANNX
Annexon
-$206.69M-$1.16N/AN/AN/AN/A-106.15%-79.82%11/9/2026 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$84.95M-$0.91N/AN/AN/AN/A-669.94%-73.97%11/10/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/6/2026 (Estimated)
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$244.17M-$0.76N/AN/AN/AN/A-103.02%-39.16%11/5/2026 (Estimated)

Latest INO, MRNA, ANNX, and SANA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.20N/AN/AN/A$2.27 millionN/A
11/9/2026Q3 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.28N/AN/AN/A$3.50 millionN/A
11/6/2026Q3 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$1.10N/AN/AN/A$890.25 millionN/A
11/5/2026Q3 2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.1478N/AN/AN/AN/AN/A
8/12/2026Q2 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.2388-$0.28-$0.0412-$0.28$6.50 millionN/A
8/12/2026Q2 2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.2167-$0.07+$0.1467-$0.07$0.53 millionN/A
8/10/2026Q2 2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.1469-$0.13+$0.0169-$0.22N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Annexon, Inc. stock logo
ANNX
Annexon
N/A
5.53
5.53
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
1.00
1.00
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/A
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
Annexon, Inc. stock logo
ANNX
Annexon
N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
88.23%

Insider Ownership

CompanyInsider Ownership
Annexon, Inc. stock logo
ANNX
Annexon
10.31%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
1.70%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
25.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Annexon, Inc. stock logo
ANNX
Annexon
92189.58 million170.03 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
112103.40 million101.64 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
142299.36 million223.32 millionOptionable

Recent News About These Companies

Sana Biotechnology (SANA) Projected to Announce Quarterly Earnings on Thursday
October 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-sana-biotechnology-sana-projected-to-announce-quarterly-earnings-on-thursday-2026-10-29/
Sana Biotechnology (NASDAQ:SANA) Sets New 1-Year Low - Here's What Happened
October 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-sets-new-1-year-low-heres-what-happened-2026-10-19/
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.7% - What's Next?
October 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-stock-price-down-67-whats-next-2026-10-13/
Sana Biotechnology: A Shot At Diabetes
October 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4953698-sana-biotechnology-a-shot-at-diabetes
Sana Biotechnology (NASDAQ:SANA) Hits New 52-Week Low - Should You Sell?
October 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-hits-new-52-week-low-should-you-sell-2026-10-12/
Sana Biotechnology, Inc. (SANA) - What Are Analysts Thinking About This Stock?
October 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-sana-biotechnology-inc-sana-what-are-analysts-thinking-about-this-stock-2026-10-10/
Sana Biotechnology, Inc. Common Stock
October 9, 2026  |  fxempire.comF
Sana Biotechnology (NASDAQ:SANA) Shares Up 3.1% - Here's Why
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sana-biotechnology-nasdaq-sana-shares-up-31-heres-why-2026-10-07/
6 'moonshot' biotech stocks that offer big risks, bigger rewards
September 23, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/6-moonshot-biotech-stocks-that-offer-big-risks-bigger-rewards/ar-AA2cNIJ1
Sana Biotechnology (SANA)
September 23, 2026  |  es.investing.comhttps://es.investing.com/equities/sana-biotechnology
Sana Biotechnology, Inc. (SANA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4949033-sana-biotechnology-inc-sana-presents-at-h-c-wainwright-28th-annual-global-investment
Sana Biotechnology op Morgan Stanley conferentie: focus op diabetes
September 15, 2026  |  nl.investing.comhttps://nl.investing.com/news/transcripts/sana-biotechnology-op-morgan-stanley-conferentie-focus-op-diabetes-93CH-914514
Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946244-sana-biotechnology-inc-sana-presents-at-morgan-stanley-24th-annual-global-healthcare
Sana Biotechnology出席富国银行医疗健康大会：两大核心项目即将进入临床阶段
September 10, 2026  |  cn.investing.comhttps://cn.investing.com/news/transcripts/article-93CH-3556440
Sana Biotechnology出席花旗2026年生物医药返校峰会：押注糖尿病疗法
September 10, 2026  |  cn.investing.comhttps://cn.investing.com/news/transcripts/article-93CH-3561461
Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945241-sana-biotechnology-inc-sana-presents-at-citigroups-biopharma-back-to-school-summit-2026
Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945095-sana-biotechnology-inc-sana-presents-at-wells-fargo-21st-annual-healthcare-conference
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
September 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-sana-biotechnology-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302870954.html
Sana Biotechnology to Present at September 2026 Investor Conferences
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354578/0/en/sana-biotechnology-to-present-at-september-2026-investor-conferences.html
As U.S.-China biotech race heats up, Seattle makes its case to D.C.
August 27, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/as-us-china-biotech-race-heats-up-seattle-makes-its-case-to-dc/ar-AA2b4klV
As US.-China biotech race heats up, Seattle makes its case to DC
August 27, 2026  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/as-us-china-biotech-race-heats-up-seattle-makes-its-case-to-dc/ar-AA2b4klV

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
MGM Resorts International logo on a gold placard mounted on a dark marble wall.
MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?
By Chris Markoch | October 4, 2026
Illustration of a balance scale with a bear figurine and declining chart on one side, a bull and rising chart on the other.
3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 Earnings
By Chris Markoch | October 6, 2026
Eli Lilly, Moderna, Guardant Health and Illumina Ride AI That Reads the Body
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
By Bridget Bennett | October 19, 2026
Domino's Pizza logo overlaid on a storefront at sunset, with a pepperoni pizza in the foreground.
Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But Up
By Thomas Hughes | October 15, 2026
Industrial manufacturing floor with CNC machining equipment, metal valves, and machined parts on a workbench.
Illinois Tool Works Faces Headwinds—2 Alternatives Stand Out
By Nathan Reiff | October 19, 2026
Annexon stock logo

Annexon NASDAQ:ANNX

$3.92 -0.14 (-3.33%)
As of 02:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$2.09 +1.48 (+246.28%)
As of 02:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna stock logo

Moderna NASDAQ:MRNA

$223.92 +2.20 (+0.99%)
As of 02:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sana Biotechnology stock logo

Sana Biotechnology NASDAQ:SANA

$2.40 -0.18 (-6.81%)
As of 02:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas